Last info update: March 2023
Ulrich goldmann email & phone, chief medical officer, senior vice president global head medical affairs at Alexion pharmaceuticals, inc.

Ulrich Goldmann — Contact Information

Chief Medical Officer, Senior Vice President Global Head Medical Affairs, Health

Ulrich Goldmann's Email, Phone & Whatsapp Number and other Contact Information

  • Emails Email u***com
    Open contact Available for registered users
  • Phones Phone +***570
    Open contact Available for registered users
  • Location Location Boston, Massachusetts, United States
  • Skills Skills Oncology · Medical Affairs · Clinical Development · Pharmaceutical Industry · Drug Development · Clinical Trials · Health Economics · Clinical Research · Healthcare · Market Access · Biotechnology · Urology · Pharmacovigilance · Leadership · Infectious Diseases · Pharmaceutics · Neurology · Hospitals · Surgery · Product Launch · Managed Care

Ulrich Goldmannis a Chief Medical Officer, Senior Vice President Global Head Medical Affairs. Works at Alexion Pharmaceuticals, Inc.(United States). Located in Boston, Massachusetts, United States. Open Ulrich Goldmann's email & phone: U***com, +***570. Skilled in Oncology · Medical Affairs · Clinical Development · Pharmaceutical Industry · Drug Development · Clinical Trials · Health Economics · Clinical Research · Healthcare · Market Access · Biotechnology · Urology · Pharmacovigilance · Leadership · Infectious Diseases · Pharmaceutics · Neurology · Hospitals · Surgery · Product Launch · Managed Care.

Experience of Ulrich Goldmann

Ulrich goldmann's Company Details

Alexion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hemat Read more ologic, kidney and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. Or the production of Soliris.

  • Company Emails [email protected]
  • Company Phone (203) 272-2596
  • Company Website alexion.com
  • Company Location boston, massachusetts, united states
  • Industry biotechnology
  • Company Size 1001-5000
  • Found Year 1992
Click to load map
Colleagues
Similar employees

Frequently Asked Questions

Directories